Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82


Test-retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer's disease.

Salinas C, Lohith TG, Purohit A, Struyk A, Sur C, Bennacef I, Beaver J, Martarello L.

J Cereb Blood Flow Metab. 2019 Nov 11:271678X19887781. doi: 10.1177/0271678X19887781. [Epub ahead of print] No abstract available.


Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.

Koole M, Lohith TG, Valentine JL, Bennacef I, Declercq R, Reynders T, Riffel K, Celen S, Serdons K, Bormans G, Ferry-Martin S, Laroque P, Walji A, Hostetler ED, Briscoe RJ, de Hoon J, Sur C, Van Laere K, Struyk A.

Mol Imaging Biol. 2020 Feb;22(1):173-180. doi: 10.1007/s11307-019-01367-w.


Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.

Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, Mo Y, Sur C, Michelson D.

N Engl J Med. 2019 Apr 11;380(15):1408-1420. doi: 10.1056/NEJMoa1812840.


Self-Controllable Secure Location Sharing for Trajectory-Based Message Delivery on Cloud-Assisted VANETs.

Park Y, Sur C, Noh SW, Rhee KH.

Sensors (Basel). 2018 Jul 1;18(7). pii: E2112. doi: 10.3390/s18072112.


Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles.

Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, Reynders T, Telan-Choing NF, Riffel K, Celen S, Serdons K, Bormans G, Tsai K, Walji A, Hostetler ED, Evelhoch JL, Van Laere K, Forman M, Stoch A, Sur C, Struyk A.

J Nucl Med. 2019 Jan;60(1):107-114. doi: 10.2967/jnumed.118.208215. Epub 2018 Jun 7.


Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D.

N Engl J Med. 2018 May 3;378(18):1691-1703. doi: 10.1056/NEJMoa1706441.


Species richness accelerates marine ecosystem restoration in the Coral Triangle.

Williams SL, Ambo-Rappe R, Sur C, Abbott JM, Limbong SR.

Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):11986-11991. doi: 10.1073/pnas.1707962114. Epub 2017 Oct 24.


Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.

Villarreal S, Zhao F, Hyde LA, Holder D, Forest T, Sondey M, Chen X, Sur C, Parker EM, Kennedy ME.

J Alzheimers Dis. 2017;59(4):1393-1413. doi: 10.3233/JAD-170056.


A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.

Mo Y, Stromswold J, Wilson K, Holder D, Sur C, Laterza O, Savage MJ, Struyk A, Scheltens P, Teunissen CE, Burke J, Macaulay SL, Bråthen G, Sando SB, White LR, Weiss C, Cowes A, Bush MM, DeSilva G, Darby DG, Rainey-Smith SR, Surls J, Sagini E, Tanen M, Altman A, Luthman J, Egan MF.

Alzheimers Dement (Amst). 2017 Mar 6;6:201-209. doi: 10.1016/j.dadm.2017.02.004. eCollection 2017.


Non-invasive bioluminescence imaging of β-cell function in obese-hyperglycemic [ob/ob] mice.

Patel M, Gleason A, O'Malley S, Connolly B, Suresch D, Virostko J, Phillips N, Lin SA, Chen TB, Klimas M, Hargreaves RJ, Sur C, Williams DL Jr, Powers AC, Bednar B.

PLoS One. 2014 Sep 8;9(9):e106693. doi: 10.1371/journal.pone.0106693. eCollection 2014.


Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans.

Joshi AD, Sanabria-Bohórquez SM, Bormans G, Koole M, De Hoon J, Van Hecken A, Depre M, De Lepeleire I, Van Laere K, Sur C, Hamill TG.

Synapse. 2015 Jan;69(1):33-40. doi: 10.1002/syn.21782. Epub 2014 Sep 24.


In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.

Hostetler ED, Joshi AD, Sanabria-Bohórquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O'Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore CA, Kane SA, Li CC, Hargreaves RJ, de Groot T, Bormans G, Van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, De Lepeleire I, Kennedy WP, Blanchard R, Marcantonio EE, Sur C, Cook JJ, Van Laere K, Evelhoch JL.

J Pharmacol Exp Ther. 2013 Nov;347(2):478-86. doi: 10.1124/jpet.113.206458. Epub 2013 Aug 23.


Visualization of mitotic arrest of cell cycle with bioluminescence imaging in living animals.

Zhang GJ, Chen TB, Davide J, Tao W, Vanko A, Connolly B, Williams DL Jr, Sur C.

Mol Imaging Biol. 2013 Aug;15(4):431-40. doi: 10.1007/s11307-013-0619-x.


Quantitative Longitudinal Imaging of Vascular Inflammation and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging Biomarkers of Cathepsin Activity and α(v)β(3) Integrin.

Lin SA, Patel M, Suresch D, Connolly B, Bao B, Groves K, Rajopadhye M, Peterson JD, Klimas M, Sur C, Bednar B.

Int J Mol Imaging. 2012;2012:189254. doi: 10.1155/2012/189254. Epub 2012 Oct 17.


A fluorogenic near-infrared imaging agent for quantifying plasma and local tissue renin activity in vivo and ex vivo.

Zhang J, Preda DV, Vasquez KO, Morin J, Delaney J, Bao B, Percival MD, Xu D, McKay D, Klimas M, Bednar B, Sur C, Gao DZ, Madden K, Yared W, Rajopadhye M, Peterson JD.

Am J Physiol Renal Physiol. 2012 Aug 15;303(4):F593-603. doi: 10.1152/ajprenal.00361.2011. Epub 2012 Jun 6.


Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328.

Harrison ST, Mulhearn J, Wolkenberg SE, Miller PJ, O'Malley SS, Zeng Z, Williams DL Jr, Hostetler ED, Sanabria-Bohórquez S, Gammage L, Fan H, Sur C, Culberson JC, Hargreaves RJ, Cook JJ, Hartman GD, Barrow JC.

ACS Med Chem Lett. 2011 Apr 18;2(7):498-502. doi: 10.1021/ml200018n. eCollection 2011 Jul 14.


[18F]Fluoroazabenzoxazoles as potential amyloid plaque PET tracers: synthesis and in vivo evaluation in rhesus monkey.

Hostetler ED, Sanabria-Bohórquez S, Fan H, Zeng Z, Gammage L, Miller P, O'Malley S, Connolly B, Mulhearn J, Harrison ST, Wolkenberg SE, Barrow JC, Williams DL Jr, Hargreaves RJ, Sur C, Cook JJ.

Nucl Med Biol. 2011 Nov;38(8):1193-203. doi: 10.1016/j.nucmedbio.2011.04.004. Epub 2011 Jul 7.


Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist.

Connolly BM, Vanko A, McQuade P, Guenther I, Meng X, Rubins D, Waterhouse R, Hargreaves R, Sur C, Hostetler E.

Mol Imaging Biol. 2012 Feb;14(1):79-87. doi: 10.1007/s11307-011-0481-7.


Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor.

Hostetler ED, Sanabria-Bohórquez S, Fan H, Zeng Z, Gantert L, Williams M, Miller P, O'Malley S, Kameda M, Ando M, Sato N, Ozaki S, Tokita S, Ohta H, Williams D, Sur C, Cook JJ, Burns HD, Hargreaves R.

Neuroimage. 2011 Feb 14;54(4):2635-42. doi: 10.1016/j.neuroimage.2010.11.014. Epub 2010 Nov 13.


The synthesis and preclinical evaluation in rhesus monkey of [¹⁸F]MK-6577 and [¹¹C]CMPyPB glycine transporter 1 positron emission tomography radiotracers.

Hamill TG, Eng W, Jennings A, Lewis R, Thomas S, Wood S, Street L, Wisnoski D, Wolkenberg S, Lindsley C, Sanabria-Bohórquez SM, Patel S, Riffel K, Ryan C, Cook J, Sur C, Burns HD, Hargreaves R.

Synapse. 2011 Apr;65(4):261-70. doi: 10.1002/syn.20842.


The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.

Jacobson MA, Kreatsoulas C, Pascarella DM, O'Brien JA, Sur C.

Mol Pharmacol. 2010 Oct;78(4):648-57. doi: 10.1124/mol.110.065771. Epub 2010 Jul 21.


Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors.

Wolkenberg SE, Sur C.

Curr Top Med Chem. 2010;10(2):170-86. Review.


Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.

Salvatore CA, Moore EL, Calamari A, Cook JJ, Michener MS, O'Malley S, Miller PJ, Sur C, Williams DL Jr, Zeng Z, Danziger A, Lynch JJ, Regan CP, Fay JF, Tang YS, Li CC, Pudvah NT, White RB, Bell IM, Gallicchio SN, Graham SL, Selnick HG, Vacca JP, Kane SA.

J Pharmacol Exp Ther. 2010 Apr;333(1):152-60. doi: 10.1124/jpet.109.163816. Epub 2010 Jan 11.


Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT).

Kossodo S, Pickarski M, Lin SA, Gleason A, Gaspar R, Buono C, Ho G, Blusztajn A, Cuneo G, Zhang J, Jensen J, Hargreaves R, Coleman P, Hartman G, Rajopadhye M, Duong LT, Sur C, Yared W, Peterson J, Bednar B.

Mol Imaging Biol. 2010 Oct;12(5):488-99. doi: 10.1007/s11307-009-0279-z. Epub 2009 Dec 4.


Resonant X-ray enhancement of the Auger effect in high-Z atoms, molecules, and nanoparticles: potential biomedical applications.

Pradhan AK, Nahar SN, Montenegro M, Yu Y, Zhang HL, Sur C, Mrozik M, Pitzer RM.

J Phys Chem A. 2009 Nov 12;113(45):12356-63. doi: 10.1021/jp904977z.


Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose.

Uslaner JM, Drott JT, Sharik SS, Theberge CR, Sur C, Zeng Z, Williams DL, Hutson PH.

Behav Brain Res. 2010 Feb 11;207(1):37-43. doi: 10.1016/j.bbr.2009.09.035. Epub 2009 Sep 30.


Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.

Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, Laskey J, Bettano KA, Kasibhatla S, Reilly JF, Sur C, Majumder PK.

Cancer Res. 2009 Sep 15;69(18):7466-72. doi: 10.1158/0008-5472.CAN-08-4385. Epub 2009 Sep 8.


Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.

Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danziger A, Regan C, Flick R, Pascarella D, Garson S, Doran S, Kreatsoulas C, Veng L, Lindsley CW, Shipe W, Kuduk S, Sur C, Kinney G, Seabrook GR, Ray WJ.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5. doi: 10.1073/pnas.0900903106. Epub 2009 Aug 26. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):18040. Seager, Matthew [corrected to Seager, Matthew A].


In vivo optical imaging of LacZ expression using lacZ transgenic mice.

Zhang GJ, Chen TB, Connolly B, Lin SA, Hargreaves R, Vanko A, Bednar B, Macneil DJ, Sur C, Williams DL.

Assay Drug Dev Technol. 2009 Aug;7(4):391-9. doi: 10.1089/adt.2009.0195.


Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18.

Hamill TG, Sato N, Jitsuoka M, Tokita S, Sanabria S, Eng W, Ryan C, Krause S, Takenaga N, Patel S, Zeng Z, Williams D Jr, Sur C, Hargreaves R, Burns HD.

Synapse. 2009 Dec;63(12):1122-32. doi: 10.1002/syn.20689.


Discovery of GlyT1 inhibitors with improved pharmacokinetic properties.

Wolkenberg SE, Zhao Z, Wisnoski DD, Leister WH, O'Brien J, Lemaire W, Williams DL Jr, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Gibson C, Ma BK, Polsky-Fisher SL, Lindsley CW, Hartman GD.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1492-5. doi: 10.1016/j.bmcl.2009.01.015. Epub 2009 Jan 10.


Discovery of N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamides as novel, selective and potent GlyT1 inhibitors.

Zhao Z, Leister WH, O'Brien JA, Lemaire W, Williams DL Jr, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Hartman GD, Lindsley CW, Wolkenberg SE.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1488-91. doi: 10.1016/j.bmcl.2008.12.115. Epub 2009 Jan 9.


A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models.

Haines BB, Bettano KA, Chenard M, Sevilla RS, Ware C, Angagaw MH, Winkelmann CT, Tong C, Reilly JF, Sur C, Zhang W.

Neoplasia. 2009 Jan;11(1):39-47.


Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways.

Zhang GJ, Chen TB, Hargreaves R, Sur C, Williams DL Jr.

Nat Protoc. 2008;3(5):891-9. doi: 10.1038/nprot.2008.52.


A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies.

Zeng Z, O'Brien JA, Lemaire W, O'Malley SS, Miller PJ, Zhao Z, Wallace MA, Raab C, Lindsley CW, Sur C, Williams DL Jr.

Nucl Med Biol. 2008 Apr;35(3):315-25. doi: 10.1016/j.nucmedbio.2007.12.002.


Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of anticancer drugs and target validation.

Zhang GJ, Chen TB, Bednar B, Connolly BM, Hargreaves R, Sur C, Williams DL.

Neoplasia. 2007 Aug;9(8):652-61.


Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission.

Sur C, Kinney GG.

Curr Drug Targets. 2007 May;8(5):643-9. Review.


Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.

Zhao Z, Wisnoski DD, O'Brien JA, Lemaire W, Williams DL Jr, Jacobson MA, Wittman M, Ha SN, Schaffhauser H, Sur C, Pettibone DJ, Duggan ME, Conn PJ, Hartman GD, Lindsley CW.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1386-91. Epub 2006 Dec 3.


Optical molecular imaging in drug discovery and clinical development.

Bednar B, Zhang GJ, Williams DL Jr, Hargreaves R, Sur C.

Expert Opin Drug Discov. 2007 Jan;2(1):65-85. doi: 10.1517/17460441.2.1.65.


Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides.

Zhao Z, O'Brien JA, Lemaire W, Williams DL Jr, Jacobson MA, Sur C, Pettibone DJ, Tiller PR, Smith S, Hartman GD, Wolkenberg SE, Lindsley CW.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5968-72. Epub 2006 Sep 20.


Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides.

Lindsley CW, Zhao Z, Leister WH, O'Brien J, Lemaire W, Williams DL Jr, Chen TB, Chang RS, Burno M, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Tsou NN, Duggan ME, Conn PJ, Hartman GD.

ChemMedChem. 2006 Aug;1(8):807-11. No abstract available.


Electric quadrupole moments of the D states of alkaline-earth-metal ions.

Sur C, Latha KV, Sahoo BK, Chaudhuri RK, Das BP, Mukherjee D.

Phys Rev Lett. 2006 May 19;96(19):193001. Epub 2006 May 18.


The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites.

Zeng Z, Chen TB, Miller PJ, Dean D, Tang YS, Sur C, Williams DL Jr.

Nucl Med Biol. 2006 May;33(4):555-63. Epub 2006 May 2.


Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.


In vitro characterization of a gamma-secretase radiotracer in mammalian brain.

Patel S, O'Malley S, Connolly B, Liu W, Hargreaves R, Sur C, Gibson RE.

J Neurochem. 2006 Jan;96(1):171-8. Epub 2005 Nov 21.


TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.

Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, Sur C, Melillo D, Bristow L, Bromidge F, Ragan I, Kerby J, Street L, Carling R, Castro JL, Whiting P, Dawson GR, McKernan RM.

J Pharmacol Exp Ther. 2006 Jan;316(1):410-22. Epub 2005 Sep 23.


A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.

Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr.

J Pharmacol Exp Ther. 2005 Apr;313(1):199-206. Epub 2004 Dec 17.


Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo.

Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL Jr, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR.

J Med Chem. 2004 Nov 18;47(24):5825-8.


Effects of typical and atypical antipsychotics on human glycine transporters.

Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C.

Schizophr Res. 2004 Nov 1;71(1):103-12.


Supplemental Content

Support Center